Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual glucagon-like peptide 1 (GLP-1)/gastric inhibitory polypeptide (GIP) receptor agonist, HS-20094, for up to $2 billion. Read More
Privately held Beckley Psytech Ltd. is to be taken over by Atai Life Sciences in an all-share deal that values the U.K. psychedelic drug specialist at $370 million. After making a $50 million investment in January 2024, Berlin-based Atai already owns 36% of Beckley. It will now issue 105 million new shares to its fellow Beckley investors, giving them 34% ownership of the merged company. Read More
New dose-escalation data from Verastem Oncology’s phase I/II cancer study in China prompted the company to say it was encouraged by the efficacy results. However, investors felt otherwise, as the stock lost about 20% of its value the day the initial results were released. Read More
With a 42% placebo-adjusted reduction in proteinuria at week 36, Vera Therapeutics Inc. met its primary endpoint in the Origin phase III trial with BAFF and APRIL dual inhibitor atacicept in treating immunoglobulin A nephropathy (IgAN) in adults. Read More
An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22 cancer types, which has identified more than 9,000 proteins from 1,000 tumors. The results reveal which proteins allow for the classification of different cancer types, biomarkers and potential therapeutic targets, which are now available to the entire scientific community. Read More
The U.S. FDA reported the launch of its in-house generative AI (GenAI) tool, dubbed Elsa, for a variety of purposes. FDA commissioner Marty Makary assuaged industry’s privacy concerns by promising that the algorithm does not train on data submitted by makers of devices and pharmaceuticals. Read More
New hires and promotions in the biopharma industry, including: Aravax, Catalyst, Curogen, Fate, Instil Bio, Latus Bio, Scholar Rock, Seismic, Stratus, Sutro, Tela Bio, Vectory. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Actuate, In8bio, Kalvista, Kymera, Lyra, Nervgen, Novartis, Opus Genetics, Pharvaris, Regeneron, Replimune, Reviva, Teva, Viatris, Vera, Verastem, Xilio. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Bluebird, Checkpoint, Eli Lilly, Fortress, Grünenthal, Nurix, Sanofi, Simris. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ascendis, GSK, Immunitybio, Kura, Kyowa Kirin, Mabwell, Moderna, Zealand. Read More
